The genus *[Campylobacter](http://doi.org/10.1601/nm.3786)* was described by Sebald and Veron \[[@R1]\] while reclassifying the genus *Vibrio*s. Since then, 32 *[Campylobacter](http://doi.org/10.1601/nm.3786)* species with nine subspecies have been identified \[[@R2]\]. Campylobacteriosis is one of the most common bacterial gastrointestinal illnesses of humans in the developed world \[[@R3]\], including in New Zealand, which has had a high notification rate \[[@R4]\].

*[Campylobacter](http://doi.org/10.1601/nm.3786)* are frequently associated with the gastrointestinal tracts of birds \[[@R5]\], particularly chickens \[[@R6]\], but have also been detected in wild birds ranging from albatross \[[@R7]\] to zebra finch \[[@R8]\]. In New Zealand, *[Campylobacter](http://doi.org/10.1601/nm.3786)* has also been isolated frequently from waterways, with the majority of isolates being attributed to wild bird sources \[[@R9]\].

Isolation and ecology {#s2}
=====================

As part of source attribution and population structure studies on *[Campylobacter](http://doi.org/10.1601/nm.3786)* \[[@R11]\], six isolates with dark-field microscopy characteristics of *[Campylobacter](http://doi.org/10.1601/nm.3786)* but non-standard agar-plate morphology were isolated from Bolton broth enrichments (LabM) subcultured onto modified charcoal cefoperazone (mCCDA) agar (Fort Richard Laboratories) after 48 h of incubation. Two isolates were from rivers (100 ml water was filtered through a 0.45 µm filter, and the filter was placed in Bolton broth). Four isolates were from wild non-native bird faeces (three starlings and one duck) collected from deposited droppings with a swab which was placed in Bolton broth with subculture to mCCDA agar after 48 h incubation. Initial enrichment and growth were performed in a microaerobic atmosphere (10 % CO~2~, 5 % O~2~, 85 % N~2~) in a variable atmosphere incubator (Don Whitley) at 42 °C. Single colonies were subcultured to Columbia horse blood agar (Fort Richard Laboratories) before storage in 15 % glycerol in nutrient broth no. 2 (Oxoid) at −80 °C. Interestingly, we have not found similar isolates from chickens \[[@R12]\], ruminants \[[@R13]\], dogs and cats \[[@R14]\] or, most importantly, from human cases of campylobacteriosis \[[@R12]\], which suggests that these isolates have a restricted host range and low virulence.

In New Zealand, freshwater quality standards are based around the use of *E. coli* counts as an indicator relating to *[Campylobacter](http://doi.org/10.1601/nm.3786)* presence \[[@R16]\] and thus human health risk. The presence of *[Campylobacter novaezeelandiae](http://doi.org/10.1601/nm.37734)* in river water may act as a confounder for this assumption, requiring modification of the quantitative microbial risk assessments.

Characteristics of the isolates are described in [Table 1](#T1){ref-type="table"}.

###### 

Characteristics of the *[Campylobacter novaezeelandiae](http://doi.org/10.1601/nm.37734)* sp. nov. isolates described in this study

  Isolate    Source          Location                        Isolation date   16S rRNA gene accession   Genome accession
  ---------- --------------- ------------------------------- ---------------- ------------------------- ------------------
  B423b^T^   Mallard duck    Palmerston North, New Zealand   Aug 2008         MK791741                  QPGR00000000
  B571b      Starling        Palmerston North, New Zealand   Sept 2008        MK791743                  --
  B716b      Starling        Palmerston North, New Zealand   Nov 2008         MK791742                  --
  B1491      Starling        Palmerston North, New Zealand   May 2009         MK791739                  QPGQ00000000
  W441b      Oroua River     Feilding, New Zealand           Oct 2008         MK791738                  --
  W677a      Pareora River   South Canterbury, New Zealand   Apr 2011         MK791740                  QPGP00000000

16S rRNA gene phylogeny {#s3}
=======================

16S rRNA gene PCR analyses were performed using crude DNA extracted by boiling \[[@R17]\], the primers and conditions described by Lane \[[@R18]\] with Sanger sequencing of the products at the Massey Genome Service (Massey University). Comparison of the sequences suggested that all the isolates were related and formed a single distinct species previously described as '*[Campylobacter](http://doi.org/10.1601/nm.3786)* sp. nov. 3' \[[@R10]\]. A 16S rRNA gene-based phylogeny was reconstructed from the 16S rRNA loci extracted from the whole genome sequenced isolates \[[@R19]\] using barrnap (<https://github.com/tseemann/barrnap>), and aligned using [mafft]{.smallcaps}version 7 \[[@R20]\]. The resulting phylogenetic tree ([Fig. 1](#F1){ref-type="fig"}) shows that the isolates (henceforth called *[Campylobacter novaezeelandiae](http://doi.org/10.1601/nm.37734)* sp. nov.) clustered together and were closest to *Campylobacter amoricus* and *[Campylobacter peloridis](http://doi.org/10.1601/nm.14289)*. Sequence alignment showed the 16S rRNA genes of the *[C. novaezeelandiae](http://doi.org/10.1601/nm.37734)* sp. nov. isolates to be on average 97.6 % similar to those of *C. amoricus* and 97.4 % similar to those of *[C. peloridis](http://doi.org/10.1601/nm.14289)*. As a check of the quality of the genome sequence \[[@R21]\], the sequences of the Sanger sequenced 16S rRNA ene PCR products and the those extracted from the whole genome sequences were compared. The whole genome 16S genes all contained a thymidine insertion at the same position compared to the 16S rRNA PCR products. *[Campylobacter](http://doi.org/10.1601/nm.3786)* species contain three copies of the 16S rRNA genes \[[@R22]\] and the 16S gene assembled is a combination of the three, whilst PCR targets only one of the genes, suggesting that one or both of the other 16S genes contain this insertion and explaining the differences between the 16S rRNA gene sequences. Apart from this insertion, the 16S rRNA gene sequences generated by PCR and whole genome sequencing were identical.

![Maximum-likelihood tree based on 16S rRNA gene sequences. The dots on the nodes represent nodes with bootstrap support \>90%.](ijsem-70-3775-g001){#F1}

Genome features {#s4}
===============

Whole genomes of three of the isolates were sequenced, assembled and examined as described previously \[[@R19]\]. The genomic DNA G+C content of the strains was estimated at 27.5 mol% using the Geneious R10 software package \[[@R23]\]. Comparisons of genome size and G+C content were performed relative to 3210 genomes available in the NCBI RefSeq database that are assigned to the genus '*[Campylobacter](http://doi.org/10.1601/nm.3786)*'. Genomes were downloaded using the NCBI genome download tool (available at <https://github.com/kblin/ncbi-genome-download>). NCBI-assigned species taxon identifiers were used to group the data. Analysis and visualizations were performed in RStudio. The genome sizes of the *[C. novaezeelandiae](http://doi.org/10.1601/nm.37734)* isolates fell within the range of *[Campylobacter](http://doi.org/10.1601/nm.3786)* ([Fig. 2](#F2){ref-type="fig"}), however the *[C. novaezeelandiae](http://doi.org/10.1601/nm.37734)* isolates possessed the lowest G+C content of all current members of the genus *[Campylobacter](http://doi.org/10.1601/nm.3786)* \[[@R24]\] ([Fig. 3](#F3){ref-type="fig"}).

![Comparison of the genome size of *[Campylobacter novaezeelandiae](http://doi.org/10.1601/nm.37734)* sp. nov. and other *[Campylobacter](http://doi.org/10.1601/nm.3786)* species](ijsem-70-3775-g002){#F2}

![Comparison of the G+C content of *[Campylobacter novaezeelandiae](http://doi.org/10.1601/nm.37734)* sp. nov. and other *[Campylobacter](http://doi.org/10.1601/nm.3786)* species.](ijsem-70-3775-g003){#F3}

Genomic average nucleotide identity (ANI) values were calculated using an ANI calculator \[[@R26]\] showing that the values between the isolates of *[C. novaezeelandiae](http://doi.org/10.1601/nm.37734)* were 99.0--100 % while the most similar of the other *[Campylobacter](http://doi.org/10.1601/nm.3786)* species was *[Campylobacter jejuni](http://doi.org/10.1601/nm.10649)* with 79.7 % ANI similarity ([Fig. 4](#F4){ref-type="fig"}).

![Average nucleotide identity (ANI) values (%) comparing *[Campylobacter novaezeelandiae](http://doi.org/10.1601/nm.37734)* sp. nov. and other *[Campylobacter](http://doi.org/10.1601/nm.3786)* taxa. The list of accession numbers is in Table S1 (available in the online version of this article).](ijsem-70-3775-g004){#F4}

Prokka version 1.14.5 \[[@R27]\] was used to annotate the three draft genomes. Roary version 3.11.2 \[[@R28]\] was used to cluster the annotated sequences and investigate the pan-genome, a clustering similarity threshold of 70 % was specified in this analysis in order to allow clustering of gene sequences that were divergent at the genus level. The three *[C. novaezeelandiae](http://doi.org/10.1601/nm.37734)* isolates contained between 1485 and 1591 coding-DNA sequences (CDSs). They shared a pan-genome of 1781 CDSs: 1395 (78 %) of which were core and 386 (21 %) of which were accessory. Even though this is a small sample size, it demonstrates significant variation in gene content between isolates of this species.

[ariba]{.smallcaps} version 2.14.1 \[[@R29]\] was used to investigate if the three genomes contained antimicrobial resistance genes using the ResFinder database \[[@R30]\], plasmids using the PlasmidFinder database \[[@R31]\], or virulence genes using the VFDB core database \[[@R32]\]. No AMR genes or plasmids were identified amongst the genomes, but one virulence gene (*Cj1427c*) was found within the genome of the type strain (B423b^T^). This gene encodes a sugar-nucleotide epimerase/dehydratase involved in capsular formation \[[@R33]\]. The reference databases used for this analysis consist of genes and genetic markers from described bacterial species, *[C. novaezeelandiae](http://doi.org/10.1601/nm.37734)* may contain novel or distantly related AMR genes, plasmids and virulence factors not yet described in these databases. For phylogenetic analyses, genome sequences derived from species type strains (as specified by <https://lpsn.dsmz.de/genus/campylobacter>) were used where available. If unavailable, RefSeq representative genomes were used. Genomes from a total of 32 *[Campylobacter](http://doi.org/10.1601/nm.3786)* species were used. *[Campylobacter mucosalis](http://doi.org/10.1601/nm.3806)* was excluded from the analysis, as RefSeq indicated that the only available genome from this species contained significant contamination. Gene clustering in Roary identified 79 core genes (and 188 soft-core genes \[occurring in 95 % of the genomes\]) that were conserved across the genus *[Campylobacter](http://doi.org/10.1601/nm.3786)*.

Phylogenies from alignments of the core gene sequences were generated in [mega]{.smallcaps}-X \[[@R34]\], using the maximum-likelihood method and the general time-reversible model. A discrete gamma distribution was used to model evolutionary rate differences among sites (five categories (+G, parameter=0.7929)). The rate variation model allowed for some sites to be evolutionarily invariable (\[+I\], 19.23 % sites). Trees with the highest log likelihood were chosen for display, and 100 bootstrap replicates were performed to estimate node support. Trees were visualized using 'ggtree' \[[@R35]\] in RStudio \[[@R36]\]. In contrast to the 16S rRNA gene sequence similarities ([Fig. 1](#F1){ref-type="fig"}), and in accordance with whole genome ANI analysis ([Fig. 4](#F4){ref-type="fig"}), phylogenetic analysis based on core gene contents supported a close relationship to *[C. cuniculorum](http://doi.org/10.1601/nm.14495)*, *[C. upsaliensis](http://doi.org/10.1601/nm.3816)*, *[C. helveticus](http://doi.org/10.1601/nm.3797)*, *[C. hepaticus](http://doi.org/10.1601/nm.29194)*, *[C. coli](http://doi.org/10.1601/nm.3790)* and *[C. jejuni](http://doi.org/10.1601/nm.10649)* ([Fig. 5](#F5){ref-type="fig"}).

![Maximum-likelihood tree based on the core genome. The dots on the nodes represent nodes with bootstrap support \>90%.](ijsem-70-3775-g005){#F5}

Phenotypic and chemotaxonomic characterization {#s5}
==============================================

MALDI-TOF protein spectra were obtained as described by Koziel *et al.* \[[@R37]\] and discriminant peaks between species were identified using the 'MALDIquant' \[[@R38]\] 'sda' \[[@R39]\] and 'crossval' \[[@R40]\] R packages. *[C. jejuni](http://doi.org/10.1601/nm.3802)* subsp. *[jejuni](http://doi.org/10.1601/nm.3802)* NCTC 11168, *[C. coli](http://doi.org/10.1601/nm.3790)* ATCC 33559^T^, *[C. hyointestinalis](http://doi.org/10.1601/nm.10648)* ATCC 33560^T^, *[C. fetus](http://doi.org/10.1601/nm.3787)* subsp *[fetus](http://doi.org/10.1601/nm.3787)* ATCC 27374^T^ and *[C. upsaliensis](http://doi.org/10.1601/nm.3816)* ATCC 43954^T^ (ESR Culture Collection) were used as controls. Representative averaged MALDI-TOF spectra and significantly discriminant peaks for different species are shown in Fig. S1.

Electron microscopy was performed as described in Wheeler *et al.* \[[@R41]\] using an FEI Quanta 200 scanning electron microscope. All isolates were spiral-shaped rods ([Fig. 6](#F6){ref-type="fig"}).

![Electron micrograph of *[Campylobacter novaezeelandiae](http://doi.org/10.1601/nm.37734)* sp. nov.](ijsem-70-3775-g006){#F6}

*Galleria mellonella* (Biosuppliers) larvae were challenged with the *[C. novaezeelandiae](http://doi.org/10.1601/nm.37734)* isolates W441b and W667a as described by Champion *et al.* \[[@R42]\] using 31G insulin syringes (Becton Dickinson) for inoculation, with incubation at 37 °C in a variable atmosphere incubator with H~2~ (5 % H~2~, 10 % CO~2~, 3 % O~2~, 82 % N~2~). Nine isolates of *[C. jejuni](http://doi.org/10.1601/nm.10649)* isolated from invasive campylobacteriosis in humans and described in Wheeler *et al.* \[[@R41]\] were used as positive controls, phosphate-buffered saline inoculated and un-inoculated caterpillars were included as negative controls. Analyses were performed in RStudio, using the 'survival' (<https://github.com/therneau/survival>) and 'survminer' (<https://github.com/kassambara/survminer>) packages. Larvae inoculated with *[C. novaezeelandiae](http://doi.org/10.1601/nm.37734)* showed lower mortality than those inoculated with the *[C. jejuni](http://doi.org/10.1601/nm.10649)* controls (*P*=0.0089). The observed relative hazard ratio of 0.53 suggested that isolates of *[C. novaezeelandiae](http://doi.org/10.1601/nm.37734)* are approximately half as virulent as isolates of *[C. jejuni](http://doi.org/10.1601/nm.10649)* in the wax moth caterpillar model. This ability to kill larvae is discordant with our observation that *[C. novaezeelandiae](http://doi.org/10.1601/nm.37734)* has not been isolated from cases of campylobacteriosis and suggest that *[C. novaezeelandiae](http://doi.org/10.1601/nm.37734)* may be a useful model organism for exploring the *G. mellonella* virulence model.

Time taken for transformation to coccoidal forms was performed as described \[[@R43]\] using Columbia horse blood agar in a microaerobic atmosphere at 42 °C. After 3 days of incubation most (80--90 %) of the bacteria are rod-shaped, but after 6 days of incubation the proportion of rod-shaped bacteria has decreased to between 10 to 30 % with the remainder of the bacteria being coccoidal. Gram staining was performed as described by Chapin and Lauderdale \[[@R44]\]. Motility was observed by dark-field microscopy. Tests for oxidase, catalase, motility, hippurate hydrolysis and nitrate reduction were performed as described by MacFaddin \[[@R45]\]. Alkaline phosphatase activity was tested using an API Campy kit (bioMérieux). Indoxyl acetate hydrolysis was tested with the modification described by On and Holmes \[[@R46]\]. Hydrogen sulphide production was tested as described by Ma *et al.* \[[@R47]\]. Cephalothin and nalidixic acid sensitivity assays were performed using [eucast]{.smallcaps}zone cut-offs \[[@R48]\] on both sheep and horse blood-containing Mueller--Hinton agar (Fort Richard Laboratories). Temperature and atmosphere requirements were examined as described by On and Holmes \[[@R49]\] on Columbia horse blood agar and using atmospheres provided by variable atmosphere incubators or gas-generating envelopes (Oxoid). Growth on MacConkey agar (Fort Richard Laboratories), nutrient agar no. 2 (Oxoid), nutrient agar plus 1 % w/v glycine and nutrient agar plus 2 % w/v NaCl was as described by On and Holmes \[[@R49]\]. Growth on and reduction of 0.1 % w/v selenite and 0.04 % w/v 2,3,5 triphenyltetrazolium (TTC) in nutrient agar no. 2 were as described by On and Holmes \[[@R49]\]. Unless otherwise mentioned, tests were performed at 37 °C in a variable atmosphere incubator with H~2~ (5 % H~2~, 10 % CO~2~, 3 % O~2~, 82 % N~2~). Control organisms were *[C. jejuni](http://doi.org/10.1601/nm.3802)* subsp. *[jejuni](http://doi.org/10.1601/nm.3802)* NCTC 11168, *[C. jejuni](http://doi.org/10.1601/nm.10649)* NCTC 11351^T^, *[C. coli](http://doi.org/10.1601/nm.3790)* ATCC 33559^T^, *[C. hyointestinalis](http://doi.org/10.1601/nm.10648)* ATCC 33560^T^, *[C. fetus](http://doi.org/10.1601/nm.3787)* subsp *[fetus](http://doi.org/10.1601/nm.3787)* ATCC 27374^T^, *[C. upsaliensis](http://doi.org/10.1601/nm.3816)* ATCC 43954^T^, *[C. lanienae](http://doi.org/10.1601/nm.3804)* LR283 and *[C. helveticus](http://doi.org/10.1601/nm.3797)* CCUG 30683. Characteristics are given in [Table 2](#T2){ref-type="table"}, and phenotypic descriptions are given below.

###### 

Phenotypic characteristics of *[Campylobacter novaezeelandiae](http://doi.org/10.1601/nm.37734)* sp. nov. as compared to other *[Campylobacter](http://doi.org/10.1601/nm.3786)* taxa

Taxa: 1, *[Campylobacter novaezeelandiae](http://doi.org/10.1601/nm.37734)* sp. nov. (*n*=6); 2, *[C. armoricus](http://doi.org/10.1601/nm.35895)*; 3, *[C. blaseri](http://doi.org/10.1601/nm.31716)*; 4, *[C. avium](http://doi.org/10.1601/nm.14649)*; 5, *[C. canadensis](http://doi.org/10.1601/nm.11507)*; 6, *[C. coli](http://doi.org/10.1601/nm.3790)*; 7, *[C. concisus](http://doi.org/10.1601/nm.3791)* ; 8, *[C. corcagiensis](http://doi.org/10.1601/nm.25739)*; 9, *C.cuniculorum*; 10, *[C. curvus](http://doi.org/10.1601/nm.3793)*; 11, *[C. fetus](http://doi.org/10.1601/nm.3787)* subsp. *[fetus](http://doi.org/10.1601/nm.3787)*; 12, *[C. fetus](http://doi.org/10.1601/nm.25750)* subsp. *[testudinum](http://doi.org/10.1601/nm.25750)*; 13, *[C. fetus](http://doi.org/10.1601/nm.3795)* subsp. *[venerealis](http://doi.org/10.1601/nm.3795)*; 14, *[C. geochelonis](http://doi.org/10.1601/nm.28656)*; 15, *[C. gracilis](http://doi.org/10.1601/nm.3796)*; 16, *[C. helveticus](http://doi.org/10.1601/nm.3797)*; 17, *[C. hepaticus](http://doi.org/10.1601/nm.29194)*; 18, *[C. hominis](http://doi.org/10.1601/nm.3798)*; 19, *[C. hyointestinalis](http://doi.org/10.1601/nm.3800)* subsp. *[hyointestinalis](http://doi.org/10.1601/nm.3800)*; 20, *[C. hyointestinalis](http://doi.org/10.1601/nm.3801)* subsp. *[lawsonii](http://doi.org/10.1601/nm.3801)*; 21, *[C. iguaniorum](http://doi.org/10.1601/nm.26528)*; 22, *[C. insulaenigrae](http://doi.org/10.1601/nm.8943)*; 23, *C.jejuni* subsp. *doylei*; 24, *[C. jejuni](http://doi.org/10.1601/nm.3802)* subsp. *[jejuni](http://doi.org/10.1601/nm.3802)*; 25, *[C. lanienae](http://doi.org/10.1601/nm.3804)*; 26, *[C. lari](http://doi.org/10.1601/nm.14290)* subsp. *[concheus](http://doi.org/10.1601/nm.14290)*; 27, *[C. lari](http://doi.org/10.1601/nm.14291)* subsp. *[lari](http://doi.org/10.1601/nm.14291)*; 28, *[C. mucosalis](http://doi.org/10.1601/nm.3806)*; 29, *[C. ornithocola](http://doi.org/10.1601/nm.29905)*; 30, *[C. peloridis](http://doi.org/10.1601/nm.14289)*;31, *[C. pinnipediorum](http://doi.org/10.1601/nm.30241)* subsp. *[caledonicus](http://doi.org/10.1601/nm.30241)*; 32, *[C. pinnipediorum](http://doi.org/10.1601/nm.30240)* subsp. *[pinnipediorum](http://doi.org/10.1601/nm.30240)*; 33, *[C. rectus](http://doi.org/10.1601/nm.3811)*; 34, *[C. showae](http://doi.org/10.1601/nm.3812)*; 35, *[C. sputorum](http://doi.org/10.1601/nm.10651)*; 36, *[C. subantarcticus](http://doi.org/10.1601/nm.17886)*; 37, *C.upsaliensis*; 38, *[C. ureolyticus](http://doi.org/10.1601/nm.20099)*; 39, *[C. volucris](http://doi.org/10.1601/nm.20003)*. +, All strains examined give a positive result; --, strains examined give a negative result; U, unknown; F, 7--28 % strains positive; V, 29--69 % strains positive; M, 70--95 % strains positive; D, unable to be determined; w, weak.

  Characteristic                    1      2    3                 4                 5    6    7        8                 9      10       11       12   13       14     15       16   17     18       19       20
  --------------------------------- ------ ---- ----------------- ----------------- ---- ---- -------- ----------------- ------ -------- -------- ---- -------- ------ -------- ---- ------ -------- -------- -----------------
  **Motility**                      \+          --                \+                \+   \+   \+       --                \+     \+       \+       \+   \+       \+     --       \+   \+     --       \+       \+
  **Oxidase**                       \+     \+   \+                \+                \+   \+   V        \+                \+     \+       \+       \+   \+       \+     --       \+   \+     \+       \+       \+
  **Catalase**                      \+     \+   \+                [w]{.smallcaps}   V    \+   --       \+                \+     --       \+       \+   M        \+     V        --   \+     --       \+       \+
  **Urease**                        --     \+   \+                --                V    --   --       \+                --     --       --       --   --       --     --       --   --     --       --       --
  **Nitrate reduction**             \+     --   \+                \+                V    \+   F        M                 \+     \+       \+       \+   M        \+     M        \+   V      --       \+       \+
  **Hippurate hydrolysis**          --     --   --                \+                --   --   --       --                --     F        --       --   --       \+     --       --   M      --       --       --
  **Indoxyl acetate hydrolysis**    \+     --   \+                \+                --   \+   --       V                 \+     V        --       --   --       --     M        \+   \+     --       --       --
  **Alkaline phosphatase**          --     --   \+                --                --   --   M        \+                --     V        --       --   --       --     --       --   U      --       --       F
  **H~2~S production TSI**          --     U    \+                --                V    --   --       \+                --     F        --       --   --       --     --       --   --     --       \+       \+
  **Alpha haemolysis**              \+     --   --                --                --   F    F        --                \+     F        --       --   V        --     --       \+   --     --       V        F
  **Growth 25 °C microaerobic**     --     --   \+                --                --   --   --       U                 --     --       \+       \+   \+       \+     --       --   --     --       F        --
  **Growth 37 °C microaerobic**     \+     \+   \+                \+                \+   \+   \+       \+                \+     V        \+       \+   \+       \+     --       \+   \+     --       \+       \+
  **Growth 42 °C microaerobic**     \+     \+   \+                \+                \+   \+   M        \+                M      V        M        V    --       --     M        \+   \+     --       \+       \+
  **Growth 37 °C anaerobic**        \+     \+   \+                --                \+   --   \+       \+                --     \+       F        \+   M        \+     \+       --   --     \+       --       [w]{.smallcaps}
  **Growth 37 °C aerobic**          --     --   --                --                --   --   --       --                --     --       --       V    --       --     --       --   --     --       --       --
  **Growth on nutrient agar**       \+     U    U                 --                --   \+   F        [w]{.smallcaps}   \+     \+       M        U    M        U      \+       M    \+     U        \+       \+
  **Growth on MacConkey**           --     U    \+                --                \+   V    --       --                --     M        M        M    V        --     M        --   --     --       V        V
  **R to nalidixic acid (30 µg**)   -\*    --   --                --                V    --   M        \+                V      \+       \+       \+   V        \+     V        --   V      V        \+       \+
  **R to cephalothin (30 µg**)      \+     R    --                \+                --   \+   --       --                M      --       --       U    --       --     --       --   M      --       F        --
  **H~2~ requirement**              --     --   --                V                 --   --   \+       --                --     \+       --       --   --       --     \+       --   --     \+       --       U
  **DNA G+C content (mol%**)        27.4   28   29                35                U    31   37--41   31.9              32.4   45--46   33--35   33   33--34   33.6   44--46   34   27.9   32--33   34--36   31--33
  **Selenite reduction**            --     V    U                 --                U    \+   F        U                 --     --       M        U    F        --     --       --   U      --       \+       \+
  **Growth on 2 % NaCl**            \+     --   U                 --                --   --   F        \+                --     V        --       U    F        \+     --       F    --     U        --       --
  **Growth on 1 % glycine**         \+     \+   [w]{.smallcaps}   --                V    M    F        \+                --     \+       \+       \+   F        \+     \+       V    \+     \+       \+       F
  **Growth on 0.04 % TTC**          F      V    U                 \+                U    \+   --       --                V      \+       --       \+   --       --     --       --   \+     --       F        --
  **TTC reduction**                 F      V    U                 --                U    \+   --       --                V      M        --       \+   --       --     --       --   U      --       F        --

  Characteristic                    21                22                 23       24       25                26   27       28       29     30   31   32   33                34       35       36   37       38       39
  --------------------------------- ----------------- ------------------ -------- -------- ----------------- ---- -------- -------- ------ ---- ---- ---- ----------------- -------- -------- ---- -------- -------- -----------------
  **Motility**                      U                 \+                 \+       \+       \+                \+   \+       \+       U      U    U    U    \+                \+       \+       \+   \+       --       \+
  **Oxidase**                       \+                \+                 \+       \+       \+                \+   \+       \+       --     \+   \+   \+   \+                V        \+       \+   \+       \+       \+
  **Catalase**                      \+                \+                 M        \+       \+                \+   \+       --       \+     \+   --   \+   F                 \+       V^†^     \+   --       F        \+
  **Urease**                        --                --                 --       --       --                --   --       --       \+     U    \+   \+   --                --       V^‡^     U    --       \+       U
  **Nitrate reduction**             \+                \+                 --       \+       \+                \+   \+       F        V      U    \+   \+   \+                \+       M        U    \+       \+       \+
  **Hippurate hydrolysis**          --                --                 \+       \+       --                --   --       --       --     --   --   --   --                --       --       --   --       --       --
  **Indoxyl acetate hydrolysis**    --                --                 \+       \+       --                U    F        --       --     U    --   --   \+                V        --       --   \+       V        --
  **Alkaline phosphatase**          U                 U                  --       --       \+                U    --       --       --     U    U    U    --                --       --       U    --       --       --
  **H~2~S production TSI**          \+                --                 --       --       --                U    --       \+       --     U    \+   \+   --                V        \+       --   --       --       --
  **Alpha haemolysis**              \+                [nd]{.smallcaps}   \+       \+       \+                U    M        F        --     U    \+   \+   \+                \+       \+       \+   \+       V        U
  **Growth 25 °C microaerobic**     \+                --                 --       --       --                --   --       --       --     U    \+   \+   --                --       --       --   --       --       --
  **Growth 37 °C microaerobic**     \+                \+                 \+       \+       \+                \+   \+       \+       \+     \+   \+   \+   --                V        \+       \+   \+       \+       \+
  **Growth 42 °C microaerobic**     --                --                 --       \+       \+                \+   \+       \+       \+     \+   --   --   [w]{.smallcaps}   V        M        \+   M        V        \+
  **Growth 37 °C anaerobic**        [w]{.smallcaps}   --                 --       --       [w]{.smallcaps}   U    --       \+       \+     U    \+   \+   \+                \+       \+       \+   --       \+       \+
  **Growth 37 °C aerobic**          --                --                 --       --       --                --   --       --       --     U    --   --   --                --       --       --   --       --       --
  **Growth on nutrient agar**       U                 \+                 \+       \+       U                 \+   \+       \+       U      \+   U    U    F                 V        M        --   \+       M        --
  **Growth on MacConkey**           U                 U                  --       --       U                 U    U        M        U      U    U    U    --                \+       V        F    --       V        [w]{.smallcaps}
  **R to nalidixic acid (30 µg**)   \+                \+                 --       --       \+                --   M        M        U      M    --   --   M                 --       M        \+   --       --       \+
  **R to cephalothin (30 µg**)      --                \+                 --       \+       \+                \+   \+       --       U      F    --   --   --                --       --       --   F        --       \+
  **H~2~ requirement**              --                --                 --       --       U                 U    --       \+       --     U    --   --   \+                \+       --       U    --       \+       --
  **DNA G+C content (mol%**)        36                U                  28--30   30--31   36                30   31--33   38--39   29.5   29   31   30   45--46            44--46   30--33   30   32--35   28--30   29
  **Selenite reduction**            U                 U                  --       M        U                 U    V        F        U      U    U    U    --                --       U        --   \+       --       \+
  **Growth on 2 % NaCl**            U                 --                 --       --       --                \+   \+       --       U      M    U    U    M                 \+       \+       \+   --       \+       --
  **Growth on 1 % glycine**         \+                \+                 F        M        --                \+   \+       V        \+     \+   --   V    M                 V        \+       M    \+       \+       --
  **Growth on 0.04 % TTC**          U                 U                  V        M        U                 U    M        --       U      U    U    U    --                --       --       U    --       \+       --
  **TTC reduction**                 U                 U                  V        M        U                 U    M        --       U      U    U    U    --                --       --       U    --       --       --

Description of *[Campylobacter novaezeelandiae](http://doi.org/10.1601/nm.37734)* sp. nov. {#s6}
==========================================================================================

*[Campylobacter novaezeelandiae](http://doi.org/10.1601/nm.37734)* (no.vae.zee.lan\'di.ae. N.L. gen. n. novaezeelandiae of Nova Zeelandia, pertaining to New Zealand).

Cells are Gram-negative, motile, spiral rods, 3--4 µm long. After 2 days incubation on Columbia horse blood agar at 37 °C in a microaerobic atmosphere containing hydrogen gas, colonies are small (0.5--1 mm), grey, smooth and entire with slightly convex surfaces. Strong, dark α-haemolysis is seen on Columbia horse blood agar. A distinctive '*[Campylobacter](http://doi.org/10.1601/nm.3786)*' odour \[[@R50]\] is produced. On mCCDA agar, colonies are small and grey with irregular margins. Isolates will grow microaerobically (without hydrogen) at 42 °C, but growth was faster at 37 °C. They grow anaerobically at 37 °C but do not grow in ambient air at 37 °C. They grow on nutrient agar, nutrient agar +1 % w/v glycine and nutrient agar +2 % w/v NaCl, but not on MacConkey agar or on nutrient agar with 0.1 % w/v selenite. Only 1/6 isolates grew on nutrient agar containing 0.04 % w/v tetrazolium chloride, that isolate was also capable of reducing tetrazolium. They grow poorly on Mueller--Hinton agar containing either sheep or horse blood. Isolates are motile and positive for oxidase, catalase, indoxyl acetate hydrolysis and nitrate reduction. They do not hydrolyse hippurate, produce H~2~S in TSI, show alkaline phosphatase activity nor do they produce urease. All isolates are resistant to cephalothin and sensitive to nalidixic acid. Pathogenicity for vertebrates is unknown and we have not isolated this species from humans or symptomatic animals \[[@R12]\]; however, they were capable of causing death in the *Galleria mellonella* larval model. The type strain is B423b^T^ (=NZRM 4741^T^=ATCC TSD-167^T^). The GenBank accession numbers for the genome assemblies of B423b^T^, B1491 and W677a are QPGR00000000, QPGQ00000000 and QPGP00000000, respectively, while the read data are deposited under SRA codes SRR8367113, SRR8367114 and SRR8367115 within the BioProject PRJNA480171. The 16S rRNA gene sequences have been deposited in GenBank under the accession numbers MK791738--MK791743.
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